500 related articles for article (PubMed ID: 26281144)
1. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
Eskandary F; Bond G; Regele H; Kozakowski N; Kikić Z; Wahrmann M; Haslacher H; Oberbauer R; Ramassar V; Halloran P; Böhmig GA
Clin Transpl; 2014; ():189-95. PubMed ID: 26281144
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
Trials; 2014 Apr; 15():107. PubMed ID: 24708575
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study.
Eskandary F; Bond G; Kozakowski N; Regele H; Marinova L; Wahrmann M; Kikić Ž; Haslacher H; Rasoul-Rockenschaub S; Kaltenecker CC; König F; Hidalgo LG; Oberbauer R; Halloran PF; Böhmig GA
Transplantation; 2017 Mar; 101(3):631-641. PubMed ID: 27120452
[TBL] [Abstract][Full Text] [Related]
4. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
5. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
[TBL] [Abstract][Full Text] [Related]
6. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
[TBL] [Abstract][Full Text] [Related]
7. B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients.
Pongpirul W; Chancharoenthana W; Pongpirul K; Leelahavanichkul A; Kittikowit W; Jutivorakool K; Nonthasoot B; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K; Townamchai N
Nephrology (Carlton); 2018 Feb; 23(2):169-174. PubMed ID: 27888573
[TBL] [Abstract][Full Text] [Related]
8. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
[TBL] [Abstract][Full Text] [Related]
10. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
Eskandary F; Regele H; Baumann L; Bond G; Kozakowski N; Wahrmann M; Hidalgo LG; Haslacher H; Kaltenecker CC; Aretin MB; Oberbauer R; Posch M; Staudenherz A; Handisurya A; Reeve J; Halloran PF; Böhmig GA
J Am Soc Nephrol; 2018 Feb; 29(2):591-605. PubMed ID: 29242250
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
[TBL] [Abstract][Full Text] [Related]
13. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
14. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts.
Alfonso J; Gralla J; Klem P; Chan L; Wiseman AC; Cooper JE
Clin Transpl; 2014; ():161-70. PubMed ID: 26281141
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
16. Microvascular inflammation in early protocol biopsies of renal allografts in cases of chronic active antibody-mediated rejection.
Tsuji T; Yanai M; Itami H; Ishii Y; Akimoto M; Fukuzawa N; Harada H; Fukasawa Y
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():26-30. PubMed ID: 26031582
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
Cooper JE; Gralla J; Chan L; Wiseman AC
Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
[TBL] [Abstract][Full Text] [Related]
18. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
[TBL] [Abstract][Full Text] [Related]
19. Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing.
Süsal C; Wettstein D; Döhler B; Morath C; Ruhenstroth A; Scherer S; Tran TH; Gombos P; Schemmer P; Wagner E; Fehr T; Živčić-Ćosić S; Balen S; Weimer R; Slavcev A; Bösmüller C; Norman DJ; Zeier M; Opelz G;
Transplantation; 2015 Sep; 99(9):1976-80. PubMed ID: 25769065
[TBL] [Abstract][Full Text] [Related]
20. De novo donor specific antibodies and patient outcomes in renal transplantation.
DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]